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Abstract 
At this time, good quality randomized clinical trials assessing the effects of vitamin D supplementation on 
cardiometabolic outcomes are lacking in the international literature. To fill this gap, the Working Group on 
Vitamin D and Cardiorenal Disorders established jointly by the Italian Society of Hypertension (SIIA) and the 
Forum in Bone & Mineral Research conceived the HYPODD study (HYPOvitaminosis D and organ Damage). 
HYPODD  is a no-profit multicenter 12-month parallel-group double-blind placebo controlled randomized 
trial aiming to assess the effects of cholecalciferol supplementation on blood pressure control, 
antihypertensive drugs consumption and progression of target organ damage in patients with essential 
hypertension and 25-hydroxyvitamin D serum level lower than 20 ng/ml (vitamin D deficiency). HYPODD is 
coordinated by the European Society Excellence Center of Hypertension of Federico II University, Naples, 
and involves 12 academic institutions in Italy (Ancona, Milan, Padua, Perugia, Rome, Siena, Trieste, Turin, 
Udine, Varese, and Verona). It has been registered at the Agenzia Italiana del Farmaco – Osservatorio sulla 
Sperimentazione Clinica del Farmaco (AIFA- OsSC) and EUDRACT sites (n° 2012-003514-14) and has been 
approved by the Ethical Committees of all the Centers involved in the study. The patients’ recruitment is 
currently underway. 
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Background and HYPODD definition. 
For many decades the vitamin D-vitamin D receptor (VDR) biological system has been considered the “key 
regulator” of calcium-phosphate homeostasis and bone metabolism (1). In the last 20 years, several clinical 
and experimental observations have significantly modified our knowledge regarding the properties and the 
activities of this biological system (2). The new evidence can be summarized in three points: i) at least 36 
different cell types express the VDR and are responsive to stimulation by 1,25-dihydroxyvitamin D; ii) a 
paracrine production of 1,25-dihydroxyvitamin D takes place in over 10 extra-renal organs, iii) the 1,25-
dihydroxyvitaminD-VDR endocrine-paracrine system directly or indirectly controls the expression of about 
3% of the whole human genome and regulates complex processes as cell differentiation and growth 
(3).Based on these acquisitions, a variety of human diseases has been related to vitamin D insufficiency or 
deficiency, respectively defined as 25-hydroxyvitamin D circulating levels lower than 30 or lower than 20 
ng/ml (4). In particular, experimental and observational studies support the contention that vitamin D 
deficiency contributes to the pathogenesis of most common cardio-metabolic disorders such as 
hypertension, type 2 diabetes and their complications, among which coronary artery disease and 
congestive heart failure(5-8). The epidemiological and clinical relevance of these observations is 
emphasized by the notion that worldwide almost 1billion people of any age have 25-hydroxyvitamin D 
circulating levels lower than 20 ng/ml (9). However, despite the large number of observational studies 
available and their relative consistency, a causal effect of vitaminD deficiency in cardiometabolic disorders 
is not definitely established. For this reason, correction of vitamin D deficiency is not officially 
recommended nowadays for cardiovascular disease prevention (10, 11). To this end, good quality 
randomized clinical trials that assess the effects of vitamin D supplementation on cardiometabolic 
outcomes are needed (12). 
The HYPOvitaminosis D and organ Damage(HYPODD) evaluation trial described in this report aims to 
contribute to fill this gap. HYPODD is a no-profit, placebo controlled trial aiming to evaluate the effects of 
cholecalciferol supplementation on blood pressure (BP) control, antihypertensive drug consumption and 
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progression of target organ damage in patients with essential hypertension and 25-hydroxyvitamin D serum 
level lower than 20 ng/ml (i.e. vitamin D deficiency). 
Objective and study design 
The main objective of HYPODD is to assess the efficacy of cholecalciferol supplementation in improving BP 
control and slow down target organ damage progression in patients with idiopathic hypertension and 
vitamin D deficiency, as indicated by a serum level of 25-hydroxyvitamin D lower than 20 ng/ml at 
enrollment. 
The study was designed as a multicenter 12-month parallel-group double-blind placebo controlled 
randomized trial. It has been conceived by the Working Group on Vitamin D and Cardiorenal Disorders 
established jointly by the Italian Society of Hypertension (SIIA) and the Forum in Bone & Mineral Research 
coordinated by the Federico II University of Naples ESH Excellence Center. HYPODD involves academic 
institutions in Ancona, Milan, Padua, Perugia, Rome (La Sapienza University), Siena, Trieste, Turin, Udine, 
Varese, and Verona. An ancillary genetic study has been further scheduled to evaluate the possible 
influence of VDR allelic variants on the main study outcomes, to be performed in collaboration with the 
“Adriano Buzzati-Traverso” Institute of the Italian National Research Council (CNR) in Naples. 
 
Inclusion and exclusion criteria 
To be eligible for participation in the study, patients must fulfill at enrollment the following criteria: a) have 
well-controlled idiopathic hypertension [i.e. systolic BP (SBP) lower than 140 mmHg and diastolic BP (DBP) 
lower than 90 mmHg at two separate clinic visits (13)]; b) follows stable anti-hypertensive drug therapy 
since for at least 4 weeks; and c) have serum levels of 25-hydroxyvitamin D levels lower than 20 ng/ml. 
Exclusion criteria are a) age lower than 35 and higher than 75 years, b) body mass index lower than 20 
Kg/m2or higher than 35 Kg/m2; c) secondary hypertension (13); d) personal or family history of rickets 
and/or osteomalacia; e) serum calcium and/or intact PTH higher than the laboratory reference range; 
primary or secondary hyperparathyroidism (14); f) glucose fasting levels higher than 126 mg/dl; g) 
glomerular filtration rate < 60 ml/min/1.73 m2; g) renal tubular acidosis (urinary pH >7, low potassium 
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serum levels and positive urinary net charge) (15); h) serum TSH level <0.5 mUI/ml o >4.5 mUI/ml (16); i) 
altered nutritional status, i.e. weight loss higher than 10% of usual weight during the last six months, 
weight loss greater than 5%of usual weight during the last 30 days, personal history positive for chronic 
diarrhea, caloric intake (estimated using a food frequency questionnaire) inappropriate for age and gender 
(17); l) personal history positive for sarcoidosis, type 1 and type 2 diabetes mellitus, nephrolithiasis, atrial 
fibrillation, atrial flutter, atrial or ventricular extrasystoles (Lown class ≥ 2); m) ECG rhythm different from 
sinus rhythm; n) drugs history positive for antiarrhythmics drugs including digitalis and/or digoxin, 
anticonvulsant drugs, glucocorticoids drugs, warfarin, magnesium, antacids with aluminium hydroxide, 
cholestyramine or colestipol, rifampicin, orlistat, bisphosphonate, and/or 25 hydroxy vitamin D. 
Recruitment 
Study Centers. This multicenter RCT will be conducted at the Hypertension Centers of Ancona, Milan, 
Naples (Federico II University, coordinator center), Padua, Perugia, Siena, Trieste, Turin, Udine, Varese, and 
Verona. 
Patients. Each Centre will receive from the coordinator center a copy of the study protocol including the list 
of the inclusion and exclusion criteria above exposed and will enroll a similar number of male and female 
participants. Altogether, the HYPODD study population will be made of 240 participants. The majority of 
centers will recruit 16 patients, whereas the Naples, Perugia and Padua centers will recruit 40, 32 and 10 
patients respectively. The patients attending the above mentioned Centers and who are willing to 
participate will receive information about the aims, content, privacy issues and risks related to participation 
in the study. After signing a written informed consent to participate, they will undergo a clinical 
examination. A letter will then be sent to their primary care physicians with a detailed description of the 
study. Each enrolled patient will be univocally identified with a sequential alphanumeric code, according to 
the enrollment order. This alphanumeric code is formed by three parts: the first part (two letters) identifies 
the recruitment center, the second part (three numbers) identifies the patient according to order of 
inclusion in the study; the third part (one letter and two numbers) identifies the clinical examination 
number.  
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Randomization. The ABIOGEN drug company has produced an active drug and an identical placebo with 
equal organoleptic properties and has proceeded to their packaging in boxes using an alphanumeric code 
including two letters and two progressive numbers identifying the study center and the patient, 
respectively. The company has also taken care of the randomization procedure allocating the patients to 
the active drug or the placebo arm by a computer generated schedule. The investigators are blinded to the 
patient allocation as the randomization list is preserved by the ABIOGEN Industries. 
Intervention. At the start of the intervention, each patient will receive a box containing a drug or placebo 
supply sufficient for the entire study. Those in the intervention group will be instructed to take 50,000 UI of 
cholecalciferol every week for 8 weeks and subsequently 50,000 UI of the same substance every month for 
ten months, whereas patients in the control arm will take the placebo preparation at the same time points. 
Both drugs and placebo will be taken orally (4). 
Biochemical and clinical evaluation. Before initiation of the treatment, the patients will undergo a clinical 
session including the collection of demographic data (age, sex, living environment, education, physical 
activity, migration status and/or cultural background), information on life style habits and clinical findings 
(personal and family history, anthropometric measurements, occurrence of selected symptoms or signs of 
clinical disorders, ongoing drug treatments) and BP measurements according to standardized procedure by  
SIIA criteria (18). The study protocol also includes the assessment of the biochemical serum, plasma and 
urinary parameters reported in table 1 and the collection of biological samples (whole blood, plasma, 
serum and urine) that will be stored in aliquots which will constitute the HYPODD biobank. The biological 
specimens will be unequivocally identified using a progressive alphanumeric code defining a) the recruiting 
center; b) the participant’s code; c) the examination date and d) the type of biological material stored 
according to criteria suggested by the Italian Society of Human Genetics[SIGU, Società Italiana di Genetica 
Umana (19)]. In addition to the above, at T=0 the patients will undergo a 1) standard 12-lead 
electrocardiogram, recorded and analysed according to Meek and colleagues (20, 21) and by Edhouse and 
colleagues (22); 2) a two- and three-dimensional transthoracic echocardiogram with acquisition of 
parameters of left and right ventricular function and geometry, including tissue-doppler procedures, 
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according to the criteria of the American Society of Echocardiography(23); 3) the assessment of central 
hemodynamic parameters [central systolic blood pressure (SBPc), central pulse pressure (PPc), 
augmentation pressure (AP), augmentation index (AIx), augmentation index adjusted for heart rate (AIx75)] 
and arterial stiffness [carotid-femoral pulse wave velocity (PWV)]. These parameters will be assessed by a 
high-fidelity applanation tonometer and analysed by the SphygmoCor device (24), 4) a carotid Doppler 
Ultrasound Scan with evaluation of the arterial intimal medial thickness (25); and 5) a24 hour ambulatory 
BP monitoring (ABPM)performed and analysed according to the ESH/ESC criteria (13).The instrumental 
tests previously listed in points 1, 2,3, 4 and 5 will be recorded and then examined in a centralized way. 
After this initial clinical assessment, the participants will receive a) a schedule for BP home monitoring, b) a 
normocaloric (2100 Kcal), normal calcium (1000 mg/day) , reduced sodium diet(1500 mg/day); c) 
appropriate suggestions to promote an increased cutaneous biosynthesis of 25-hydroxy vitamin D, 
according to the International Osteoporosis Foundation (IOF)(20).  
Monitoring. A monthly clinical evaluation of the enrolled participants is planned (figure 1). At each clinic 
visit BP is measured and the patient’s pharmacological treatment is checked and modified, if necessary, 
according to the flow-chart shown in figure 2. The antihypertensive treatment is reduced if, at two 
consecutive monthly clinical evaluations, SBP is lower than 130 mmHg andDBP lower than 85 mmHg. In 
patients taking a single drug, the drug dosage will be halved until the minimum dosage reported in table 2. 
If this minimum dosage is reached and a further dosage reduction is necessary, the physician stops  the 
drug administration. In patients assuming two or more antihypertensive drugs, the physician first reduces 
the dosage of one of the two drugs, according to the subsequent stepwise schedule: 1st)Diuretic; 2nd) Beta-
blocker; 3rd) Calcium antagonist; 4th) Renin-Angiotensin-Aldosterone (RAAS) inhibitor. Conversely, the 
pharmacological treatment is  increased if a) SBP is higher than 160 mmHg and/or  DBP is higher than 95 
mmHg; b) SBP is higher than 140 mmHg and/or the DBP is higher than 90 mmHg and the mean of home 
diary BP measurements is higher than 130 mmHg for SBP and higher than 85 mmHg for DBP; c) at two 
consecutive monthly clinic visits, SBP is higher than 140 mmHg and/or DBP is higher than 90 mmHg. In 
patients taking a single drug, the drug dosage is  increased until the maximum dosage reported in table 1 
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or, alternatively, the physician may add another antihypertensive drug according to the subsequent 
schedule: 1st choice RAAS inhibitor; 2nd) Calcium antagonist; 3rd) Beta-blocker; 4th) Diuretic. In patients 
taking combination therapy, the physician  increases the dosage of one of the drugs being currently used to 
reach the maximum dosage reported in table 1 or, alternatively, another antihypertensive drug can be 
added according to the previously reported schedule. 
At days 120, 240 and 360 (i.e. T=120, T=240 and T=360), biochemical serum and urinary parameters are 
measured and biological samples (whole blood, plasma, serum and urine) are collected and  stored in 
aliquots in the HYPODD biobank. At the end of the study (T= 360), in addition to biochemical analyses, 
clinical examinations aimed at the assessment of target organ disease are performed as at the enrollment 
(T= 0).A flow chart of the study is given in Figure 1. 
Study endpoints and outcome measures 
The first primary endpoint of the study is the assessment of the effect of cholecalciferol supplementation 
on the consumption of antihypertensive drugs during the study needed to maintain optimal BP control, 
according to the ESH/ESC criteria (13). The consumption of antihypertensive drugs at the end of the study 
(T=360) minus the one at patients’ enrollment (T=0) is the outcome measure for this endpoint. 
A further primary endpoint is the evaluation of the effect of cholecalciferol supplementation on the 
progression of organ damage. This is a composite endpoint and its outcome measures are the 
echocardiographic -estimated left ventricular mass, the aPWV, the albuminuria levels and the atrial 
natriuretic peptides plasma levels.  
Sample size calculation. The sample size of the HYPODD study was estimated based on an expected  
reduction in antihypertensive drug consumption of 20% or more in the vitamin D intervention group 
compared with the placebo group at T=360 (power: 80%; alpha error: 5%). In addition, the HYPODD study is 
expected to have a power of 80% (alpha error: 5%) to identify a statistically significant reduction of left 
ventricular mass equal to or greater than 7 g/m2.7 and/or a reduction of PWV equal to or greater than 0.9 
m/s, and/or a reduction of albuminuria levels equal to or greater than 45 mg/24h, and/or a reduction of 
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atrial natriuretic peptide plasma levels equal to or greater than 600 fmol/ml between the two study 
cohorts. A dropout rate of up to 15% was taken into account in the sample size calculation. 
Statistics. The statistical analyses will be performed using the Statistical Package for the Social 
Sciences(SPSS) version 12. The Student’s T test, with Bonferroni correction when required, and contingency 
χ2-table will be used for univariate analysis of interval and nominal variables, respectively. Linear regression 
analysis and Pearson’s correlation will be performed to detect possible associations between the variables 
under study. Non-parametric tests will be used for nominal variables. Logistic regression models will be 
generated, based on the results of univariate analyses, to assess the relative impact of interrelated factors 
on the outcome variables . The genetic data obtained from the ancillary study will be analyzed using the 
FINETTI program at http://ihg.ghs.de/cgi-bin/hw/hwa1.pl and the Estimated Haplotype Linkage Program 
version 5.1. 
Ethics and legal aspects 
HYPODD is a no-profit study. The study costs are partially covered by a SIIA research grant (to LDE). 
The ABIOGEN Industries support the study by providing  the drug and placebo preparations at no cost ; they 
are also in charge of the participants’ random allocation to one or the other treatment arm and the only 
ones aware of the participants allocation. According to the Declaration of Helsinki (27) and to the criteria of 
the Convention of Oviedo (28), each patient enrolled for this study is required to sign an informed consent 
for collection and storage of clinical data and biological materials and for their use for diagnostic and 
research purposes, without any financial interest. The signed informed consent includes the explicit 
possibility of withdrawing the given consent at any time. All biological samples are identified using an 
unambiguous and progressive alphanumeric code and stored according to the SIGU criteria (19). The 
criteria for identification, storage and eventual destruction of the biological samples are clearly declared on 
the informed consent model. The dosage at which  cholecalciferol is administered during the study is the 
one suggested by Holick for the correction of  vitamin D deficiency and supported by the Endocrine Society 
(4, 29). The antihypertensive treatment protocol conforms to the ESH/ESC guidelines for the clinical 
management of hypertension (13). Based on the above considerations, participation to the study is at no 
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added risk for the participants as compared to that inherent to the currently recommended treatment of 
high BP and vitamin D deficiency. 
Study strengths and limitations. 
Major strengths of the study are its multicenter randomized controlled trial design and the double 
blindness of both the participants and the trial investigators to the patients’ treatment allocation.  
During the entire study, BP is monitored and maintained within the limits recommended by the ESH/ESC 
guidelines for hypertension management (13) in both study cohorts (active drug and placebo). The effects 
of BP optimal control on the biochemical and clinical  indices of organ damage are  thus equally distributed 
in both study cohorts. Thus, any difference in the antihypertensive drug consumption and/or in the clinical 
expression of organ damage between the two study cohorts will be reasonably attributable to the 
correction of vitamin D deficiency in the active drug study cohort.  
The major study limitation is the absence of “hard” cardiovascular endpoints (i.e. cardiovascular morbidity 
and mortality) due to the lack of the necessary budget.  
Perspectives 
Depending on HYPODD study results, substantial innovations could be proposed for the diagnostic process 
and the treatment protocol of high BP. The study could help clarify important aspects of  the extraskeletal 
biological activities of the vitamin D system, providing novel evidence in this respect that could be the basis 
for the design and the implementation of larger trials with harder endpoints. The ancillary genetic study 
aiming to the assessment of the possible influence of VDR allelic variants on the main study outcomes may 
provide further important information on the pathophysiological bases of the cardiovascular and metabolic 
effects of the vitamin D system. In general, the biological bank  created in connection with HYPODD 
implementation may inspire further studies in this area. 
Trial status. 
The HYPODD study has been registered at the Agenzia Italiana del Farmaco – Osservatorio sulla 
Sperimentazione Clinica del Farmaco (AIFA- OsSC) and EUDRACT sites (n° 2012-003514-14) and has been 
approved by the Carlo Romano Ethical Committee of the Federico II University (prot. 41/12). The study 
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protocol has been submitted to all the Ethical Committees of the participating Centers and received their 
approval. The patients recruitment is currently underway at all Centers.  
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Figure Legends 
Figure 1. 
HYPODD study. flow chart. T: time expressed in days. BP: blood pressure. ECG: electrocardiogram. US: 
ultrasonography. ABPM: 24h-ambulatory blood pressure measurement.  
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Figure 2. 
HYPODD study: decision-making. ABP: ambulatory blood pressure measurement. HBP: home blood 
pressure measurement. A: In patients taking a single drug, the drug dosage will be halved until the 
minimum dosage reported in table 1. If this minimum dosage is reached and an ulterior dosage reduction is 
necessary, the physician will interrupt the drug administration. In patients assuming two or more 
antihypertensive drugs, the reduction of anti-hypertensive drugs should occur according to this diagram: 
1st) Diuretics; 2nd) Beta-blocker; 3rd) Calcium antagonist; 4th) Renin-Angiotensin-Aldosterone (RAAS) 
inhibitor. B:  In patients taking a single drug, the drug dosage will be increased until the maximum dosage 
reported in table 1 or, in alternative, the physician could added another antihypertensive drug according to 
this diagram: 1st) RAAS inhibitor; 2nd) Calcium antagonist; 3rd) Beta-blocker; 4th) Diuretic 
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Table 1 
Biochemical parameters assessed in the HYPODD study cohorts 
Serum and plasma parameters Complete Blood Count  
Glucose Sodium Urinary parameters  
Insulin Potassium pH  
Total Cholesterol C-reactive Protein  Cortisol ⃰  
HDL- Cholesterol TSH ⃰ Proteinuria ⃰  
LDL- Cholesterol 25 hydroxy vitamin D ⃰ Albuminuria ⃰  
Triglycerides PTH ⃰ Total Calcium ⃰  
Creatinine Renin ⃰ Magnesium ⃰  
Total Calcium Aldosterone ⃰ Phosphate ⃰  
Albumin Pro atrial natriuretic peptides ⃰ Citrate ⃰  
Magnesium  Sodium⃰  
Phosphate  Potassium⃰  
Chloride  Urate⃰  
 
HDL High Density Lipoprotein; LDLLow Density Lipoprotein. ⃰ parameters measured on biological 
specimens stored at the HYPODD biobank.  
 
